How to define people at a high risk of pancreatic cancer
Authors:
Petr Dítě 1
; E. Geryk 2; M. Jelšíková 1; I. Novotný 3; J. Trna 4; Arnošt Martínek 1
; H. Nechutová 4
Authors place of work:
Akademické centrum gastroonkologie Lékařské fakulty OU Ostrava, vedoucí lékař prof. MUDr. Petr Dítě, DrSc.
1; Ekonomický odbor FN Brno, ředitel MUDr. Roman Kraus, MBA
2; Gastroenterologické oddělení Masarykova onkologického ústavu Brno, vedoucí oddělení MUDr. Milana Šachtová, CSc. et Ph. D.
3; Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Aleš Hep, CSc.
4
Published in the journal:
Vnitř Lék 2012; 58(7 a 8): 195-198
Category:
60th Birthday prof. MUDr. Miroslav Souček, CSc.
Summary
Pancreatic cancer is a disease with exceptionally poor prognosis. This is mainly due to late diagnosis; surgical resection, as the only currently available curative method, cannot be performed if diagnosed late. It is known that 5-year survival does not exceed 5.0% and, similarly, the number of new diagnoses worldwide per calendar year equals the number of deaths per calendar year, i.e. 300,000 people. So far, no effective screening for pancreatic cancer is available in asymptomatic people. Therefore, identification of risk factors with respect to possible induction of cancerous growth, and their bearers, provides some hope. These factors include hereditary diseases such as Peutz-Jeghers syndrome, familial intestinal polyposis, melanoma mole, hereditary pancreatitis or family history of pancreatic cancer. In addition to the genetic factors, a number of initially benign diseases, such as chronic pancreatitis, diabetes mellitus or obesity, are also among risk factors. An international consortium of representatives from 15 countries has recently developed this screening alternative with the aim to actively identify people who are at risk of pancreatic cancer, examine their family members and provide subsequent regular follow-up using mainly the CECT and endosonography.
Key words:
pancreatic cancer – risk factors – chronic inflammation – genetic disorders
Zdroje
1. IARC. Globocan 2008. Lyon: IARC. http://globocan.iarc.fr/.
2. ÚZIS. Novotvary 2009 ČR. ÚZIS ČR 2012.
3. Dítě P, Geryk E. Trends of primary and subsequent cancers of gastrointestinal tract in Czech population, 1976–2005. Dig Dis 2010; 4: 1–13.
4. Konečný M, Geryk E, Kubíček P et al. Prevalence nádorů v České republice, 1989–2005–2015. Brno: PřF MU 2008.
5. Yamaguchi K, Kinoshita H, Hokazono K et al. Familial pancreatic cancer: report of one Japanese family. J Hepatobiliary Pancreat Surg 2004; 11: 434–437.
6. Whitcomb DC, Applebaum S, Martin SP. Hereditary pancreatitis and pancreatic carcinoma. Ann N Y Acad Sci 1999; 880: 201–209.
7. Latchford A, Greenhalf W, Vitone LJ et al. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg 2006; 93: 1446–1455.
8. Goldstein AM, Chan M, Harland M et al. Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66: 9818–9828.
9. Lynch HT, Brand RE, Lynch JF et al. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 12–31.
10. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076–2083.
11. Calle EE, Murphy TK, Rodriguez C et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9: 403–410.
12. Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504–511.
13. Platts J. Insulin therapy and cancer risk in diabetes mellitus. Clin Med 2010; 10: 509–512.
14. Bracci PM. Obesity and pancreatic cancer: Overview of epidemiologic evidence and biologic mechanism. Mol Carcinog 2012; 51: 53–63.
15. Lin Y, Kikuchi S, Tamakoshi A et al. JACC Study Group. Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer 2007; 120: 2665–2671.
16. Whitcomb DC, Pogue-Geile K. Pancreatitis as a risk for pancreatic cancer. Gastroenterol Clin North Am 2002; 31: 663–678.
17. Yamaguchi K, Ohuchida J, Ohtsuka T et al. Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas. Pancreatology 2002; 2: 484–490.
18. Nakaizumi A, Tanaka S, Oshikawa O et al. Branch duct type IPMN concomitant with usual invasive ductal carcinoma. Tan to Sui 2002; 23: 1013–1019.
19. Tada M, Kawabe T, Arizumi M et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol 2006; 4: 1265–1270.
20. Uehara H, Nakaizumi A, Ishikawa O et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papilary mucinous neoplasm of the pancreas. Gut 2008; 57: 1561–1565.
21. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.
22. Polesel J, Talamini R, Negri E et al. Dietary habits and risk of pancreatic cancer: an Italian case-control study. Cancer Causes Control 2010; 21: 493–500.
23. Otsuki M, Tashiro M. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern Med 2007; 46: 109–113.
24. de Vos tot Nederveen Cappel WH, Lagen-dijk MA, Lamers CB et al. Surveillance for familial pancreatic cancer. Scand J Gastroenterol Suppl 2003; 239: 94–99.
25. Lowenfels AB, Maisonneuve P, Whitcomb DC et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001; 286: 169–170.
26. Ogawa Y, Tanaka M, Inoue K et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002; 94: 2344–2349.
27. Trna J, Dítě P, Adamcová M et al. Diabetes Mellitus in Pancreatic Cancer Patients in the Czech Republic – Sex Differences? Exp Diab Res 2012; přijato do tisku.
28. Stolzenberg-Solomon RZ, Graubard BI, Chari S et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872–2878.
29. Call R, Griemsley M, Cadwallader L et al. Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic and colorectal research. Postgrad Med 2010; 122: 158–165.
30. De Waele B, Vanmierlo B, Van Nieuwenhove Y et al. Impact of body overweight and class I, II and III obesity on the outcome of acute biliary pancreatitis. Pancreas 2006; 32: 343–345.
31. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a metaanalysis of prospective studies. Int J Cancer 2007; 120: 1993–1998.
32. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 2001; 93: 937–941.
33. Reuter S, Gusta SC, Chaturvedi MM et al. Oxidative stress, inflammation and cancer: how are they linked? Free Radic Biol Med 2010; 49: 1603–1616.
34. Gallicchio L, Kouzis A, Genkinger JM et al. Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med 2006; 2: 200–205.
35. Yadav D, Hawes RH, Brand RE et al. Whitcomb DC; North American Pancreatic Study Group. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med 2009; 169: 1035–1045.
36. Dítě P, Trna J, Bělobrádková J et al. Pankreatický karcinom – vztah k diabetes mellitus a kouření. Vnitř Lék 2011; 57: 159–162.
37. Tramacere I, Scotti L, Jenab M et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose risk relation. Int J Cancer 2010; 126: 1474–1486.
38. Nishi M, Ohba S, Hirata K et al. Dose-response relationship between coffee and the risk of pancreas cancer. Jpn J Clin Oncol 1996; 26: 42–48.
39. Gullo L, Pezzili R, Morselli-Labate AM. Italian Pancreatic Cancer Study Group. Coffee and cancer of the pancreas: an Italian multicenter study. Pancreas 1995; 11: 223–229.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2012 Číslo 7 a 8
Najčítanejšie v tomto čísle
- Myocardial infarction the young – our results and experience
- An anaesthesiologist’s perspective on requirements for pre-surgery examinations
- Megakaryopoesis and platelet genesis
- Aldosterone antagonists in chronic heart failure treatment